A detailed history of Bayesian Capital Management, LP transactions in Argenx Se stock. As of the latest transaction made, Bayesian Capital Management, LP holds 450 shares of ARGX stock, worth $283,495. This represents 0.03% of its overall portfolio holdings.

Number of Shares
450
Holding current value
$283,495
% of portfolio
0.03%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$434.22 - $551.9 $195,399 - $248,355
450 New
450 $244,000
Q4 2023

Feb 14, 2024

BUY
$338.91 - $506.01 $440,583 - $657,813
1,300 Added 119.82%
2,385 $907,000
Q3 2023

Nov 14, 2023

BUY
$369.35 - $548.43 $400,744 - $595,046
1,085 New
1,085 $533,000
Q1 2023

May 15, 2023

SELL
$334.23 - $403.65 $133,692 - $161,460
-400 Reduced 7.99%
4,607 $1.72 Million
Q4 2022

Feb 14, 2023

BUY
$342.17 - $402.31 $1.3 Million - $1.53 Million
3,811 Added 318.65%
5,007 $1.9 Million
Q3 2022

Nov 14, 2022

BUY
$343.2 - $395.75 $410,467 - $473,317
1,196 New
1,196 $422,000
Q1 2020

May 15, 2020

SELL
$108.83 - $165.23 $163,353 - $248,010
-1,501 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$106.59 - $164.21 $159,991 - $246,479
1,501 New
1,501 $241,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.9B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Bayesian Capital Management, LP Portfolio

Follow Bayesian Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bayesian Capital Management, LP with notifications on news.